The HUSERMET Project
the human serum metabolome in health and disease...

    

Ovarian Cancer Study


Ovarian cancer is the fourth most common cancer in women, affecting more than 6,000 women in the UK each year. A number of chemotherapeutic agents for the treatment of ovarian cancer are available:

  • e.g. paclitaxel, caelyx and topotecan
  • Chemotherapy is carried out in 3-weekly cycles, with up to 6 cycles performed


At present at least two cycles of chemotherapy must be administered before it is clear whether the patient is responding to treatment.

  • Metabolomic biomarkers may help manage the condition by:
    • Predicting the effectiveness of a drug treatment and assessing drug resistance
    • Predicting the patients response (e.g. side effects or adverse reactions to treatment)
  • This would allow problems to be identified at an early stage and alternative treatment strategies to be employed
    • This would benefit both the patient and the health service as it would limit the use of ineffective drug treatments
  • Furthermore, the identification of biomarkers for ovarian cancer could also offer a tool for screening the general population for the disease


The primary questions for the ovarian cancer study are:

  • Can biomarkers for the diagnosis and classification of ovarian cancer be identified?
  • Can these biomarkers be used to predict/detect an adverse response to treatment at an early stage?
  • Can the response of the tumour to drugs be predicted?


Recruitment of patients into this study was carried out at Christie Hospital.







News
[25 Sep. 2012]
HUSERMET represented at Metabomeeting 2012
[Read More...]
[30 Jun. 2011]
New Publication in Nature Protocols
[Read More...]
[23 Jan. 2010]
Manchester Researcher Appointed New 'Dementia Tsar'
[Read More...]
[04 Jan. 2010]
Newly Appointed Data Analyst
[Read More...]
[01 Nov. 2009]
Recruitment Finished
[Read More...]
[01 Aug. 2009]
Two New Publications
[Read More...]
[14 Apr. 2009]
Newly Appointed Research Technician
[Read More...]
[19 Nov. 2008]
New Project Manager
[Read More...]
[12 Sept. 2008]
HUSERMET Researchers Look to the Metabolome for Answers
[Read More...]
[07 Jul. 2008]
The University of Manchester and GSK Strike New Research Alliance
[Read More...]
[07 Jul. 2008]
Prof Doug Kell is the New Chief Executive for BBSRC
[Read More...]
[10 Dec. 2007]
The Maturing Field of Metabolomics is Taking Steps Toward Guiding Personalized Nutrition
[Read More...]
[24 Aug. 2007]
Free Health 'MOTs' in World's Biggest Male Ageing Study
[Read More...]
[20 Feb. 2007]
Newly Appointed Bioanalytical Scientist for the HUSERMET Project
[Read More...]